drugset / Trial / NCT06807424

A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

NCT06807424

Phase 3 Recruiting 750 enrolled Janssen Research & Development, LLC
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of icotrokinra (JNJ-77242113) compared to placebo in biologic-experienced and biologic-naive participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.

Timeline

Start
2025-01-09
Primary completion
2027-02-10
Completion
2028-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Icotrokinra Peptide

Indications